For an adult with overactive bladder (urgency, frequency, urge incontinence) who has failed behavioral therapy, what is the recommended first‑line medication, initial dose, dose titration, contraindications, monitoring parameters, and alternative treatment options?

Mirabegron for Overactive Bladder: Comprehensive Management Guide

First-Line Treatment Recommendation

Beta-3 adrenergic agonists, specifically mirabegron, are now preferred over antimuscarinics as first-line pharmacologic therapy for overactive bladder after behavioral interventions, due to superior tolerability and absence of cognitive risk. 1

---

Mandatory Behavioral Therapy Before or Alongside Medication

• All patients must begin with behavioral interventions—including bladder training, pelvic floor muscle training, and fluid management—before or concurrent with any pharmacologic treatment, as these strategies demonstrate efficacy equal to antimuscarinic medications. 1
• Behavioral therapies should be continued for 8–12 weeks to assess effectiveness before escalating to pharmacotherapy alone. 1
• Weight loss in obese patients can reduce incontinence episodes by up to 47%. 1

---

Mirabegron: Initial Dosing and Titration

Standard Adult Dosing

• Start mirabegron at 25 mg once daily, with efficacy demonstrated within 8 weeks; if response is inadequate after 4–8 weeks, increase to 50 mg once daily. 1, 2
• The 50 mg dose provides superior efficacy compared to 25 mg for reducing incontinence episodes, micturitions, and urgency episodes per 24 hours. 3

Special Population Dosing

• Older adults (≥65 years) with multiple comorbidities: Start with 25 mg once daily, which provides both safety and therapeutic efficacy without serious adverse events. 2
• Renal impairment (eGFR 30–89 mL/min/1.73 m²): Start 25 mg, maximum 50 mg daily. 2
• Hepatic impairment (Child-Pugh Class A): Start 25 mg, maximum 50 mg daily. 2
• Elderly patients with low detrusor contractility, central nervous system lesions, or men with benign prostatic hyperplasia: Start with 25 mg and titrate to 50 mg if needed. 4

---

Contraindications and Precautions

Absolute Advantages Over Antimuscarinics

• Mirabegron can be used safely in patients with narrow-angle glaucoma, history of urinary retention, or impaired gastric emptying—all of which are contraindications to antimuscarinic agents. 1
• Mirabegron lacks anticholinergic effects and does not increase cognitive impairment risk, making it particularly suitable for elderly patients and those with cognitive concerns. 1

Relative Contraindications and Cautions

• Severe uncontrolled hypertension requires caution, as mirabegron can cause dose-dependent blood pressure increases. 2
• Frail patients (those with mobility deficits, unexplained weight loss, weakness, or existing cognitive deficits) require heightened caution with all OAB medications due to a narrower therapeutic index. 1

Pre-Treatment Assessment in Men

• In elderly men, measure post-void residual volume; if ≥250 mL or maximum flow rate <10 mL/s, bladder outlet obstruction is present and an alpha-blocker should be used first-line rather than mirabegron or antimuscarinic monotherapy. 2

---

Monitoring Parameters

• Periodically monitor blood pressure, especially in hypertensive patients and during initial treatment, as mirabegron can cause dose-dependent increases. 2
• Assess treatment response at 4–8 weeks using voiding diaries to document changes in incontinence episodes, micturitions per 24 hours, urgency episodes, and nocturia. 1, 5
• Monitor for common adverse events (>2%): hypertension, urinary tract infection, and headache. 2
• Watch for rare but serious adverse effects: angioedema of face/lips/tongue/larynx, cardiac arrhythmias, kidney stones, and serious skin reactions. 2

---

Management of Inadequate Response

Sequential Approach

• If mirabegron 25 mg provides insufficient symptom control after 4–8 weeks, increase to 50 mg once daily before considering alternative strategies. 1, 4
• If mirabegron 50 mg monotherapy fails, switch to an antimuscarinic agent (e.g., tolterodine extended-release 4 mg or solifenacin 5 mg) rather than abandoning pharmacotherapy entirely. 1, 4

Combination Therapy

• For patients refractory to mirabegron 50 mg monotherapy, add solifenacin 5 mg once daily—this combination demonstrates statistically superior efficacy compared to either monotherapy for reducing incontinence episodes, urgency, and nocturia. 6, 2
• The SYNERGY trials provide the strongest evidence for the specific combination of mirabegron 50 mg plus solifenacin 5 mg. 1, 2
• Combination therapy carries slightly increased rates of dry mouth, constipation, dyspepsia, and urinary retention compared to monotherapy. 2
• Do not use combination therapy as first-line treatment; reserve it specifically for patients who remain symptomatic despite adequate monotherapy trials. 2

---

Alternative Treatment Options

When Mirabegron Is Not Tolerated or Contraindicated

• Tolterodine extended-release 4 mg once daily is the preferred antimuscarinic alternative, offering comparable efficacy with better tolerability than immediate-release formulations. 1
• Solifenacin 5 mg once daily is another effective option, particularly if combination therapy may become necessary later. 1, 6
• Fesoterodine provides superior efficacy to tolterodine in adults ≥80 years (number-needed-to-benefit of 18 for continence). 1

Third-Line Options for Refractory Cases

• Intradetrusor onabotulinumtoxinA injections are reserved for patients who have failed both behavioral and pharmacologic therapy; patients must be able to perform self-catheterization if needed. 1
• Sacral neuromodulation (SNS) offers durable effects but requires a surgical procedure. 1
• Peripheral tibial nerve stimulation (PTNS) is less invasive but requires ongoing office visits. 1

---

Common Pitfalls to Avoid

• Do not prescribe mirabegron or any OAB medication without first instituting or reinforcing behavioral therapies—this is the most common error in OAB management. 1
• Do not discontinue mirabegron after inadequate response without first attempting dose escalation to 50 mg or switching to an antimuscarinic agent. 1, 4
• Do not use combination therapy as initial treatment; it is reserved for patients refractory to monotherapy. 2
• Do not overlook blood pressure monitoring, especially in hypertensive patients, as mirabegron can elevate blood pressure. 2
• In elderly men, do not start OAB pharmacotherapy without first assessing for bladder outlet obstruction via post-void residual measurement. 2

---

Efficacy and Tolerability Profile

• Mirabegron 50 mg once daily significantly reduces incontinence episodes (mean reduction -1.63 per 24 hours), micturitions (mean reduction -1.75 per 24 hours), and urgency episodes compared to placebo. 3
• Dry mouth occurs in only 2.1% of mirabegron 50 mg recipients versus 8.6% with tolterodine extended-release 4 mg, confirming superior tolerability. 7
• Real-world persistence rates for mirabegron monotherapy are 68.0% at 3 months, 54.4% at 6 months, and 39.4% at 12 months; treatment-naïve patients demonstrate better persistence than those previously treated with antimuscarinics. 5
• Mirabegron demonstrates consistent efficacy across age groups (<65 vs ≥65 years) and sexes, with no previously unreported safety concerns identified in large integrated databases. 8